TY  - JOUR
AU  - Haselmann, Verena
AU  - Gebhardt, Christoffer
AU  - Brechtel, Ingrid
AU  - Duda, Angelika
AU  - Czerwinski, Claudia
AU  - Sucker, Antje
AU  - Holland-Letz, Tim
AU  - Utikal, Jochen
AU  - Schadendorf, Dirk
AU  - Neumaier, Michael
TI  - Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
JO  - Clinical chemistry
VL  - 64
IS  - 5
SN  - 1530-8561
CY  - Washington, DC
PB  - American Association for Clinical Chemistry
M1  - DKFZ-2018-01849
SP  - 830 - 842
PY  - 2018
N1  - 317
AB  - The current standard for determining eligibility of patients with metastatic melanoma for BRAF-targeted therapy is tissue-based testing of BRAF mutations. As patients are rarely rebiopsied, detection in blood might be advantageous by enabling a comprehensive assessment of tumor mutational status in real time and thereby representing a noninvasive biomarker for monitoring BRAF therapy.In all, 634 stage I to IV melanoma patients were enrolled at 2 centers, and 1406 plasma samples were prospectively collected. Patients were assigned to 3 separate study cohorts: study 1 for assessment of circulating tumor DNA (ctDNA) as part of companion diagnostics, study 2 for assessment of ctDNA for patients with low tumor burden and for follow-up, and study 3 for monitoring of resistance to BRAF inhibitor (BRAFi) or mitogen-activated protein kinase inhibitor therapy.Overall, a high degree of concordance between plasma and tissue testing results was observed at 90.9
LB  - PUB:(DE-HGF)16
C6  - pmid:29483107
DO  - DOI:10.1373/clinchem.2017.281543
UR  - https://inrepo02.dkfz.de/record/141330
ER  -